NVCRNovoCure Ltd.Finished
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
Pancreas Adenocarcinoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
8 insiders sold shares within a month
Since Jun 4, 2026 · was worth 10, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 571 (final count)
- Started
- May 10, 2018
- Main results expected
- Oct 16, 2024
- Fully finished
- Oct 16, 2024
- Results posted
- Jan 21, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival of Subjects Treated With TTFields Concomitant With Gemcitabine and Nab-paclitaxel vs Chemotherapy Alone
Measured over: From randomization until death from any cause or last known alive.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.7, since 2026-06-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03377491 · record last updated 2026-01-21 · checked 2026-11-09 15:47 UTC